Two years after Ebola infection, survivors exhibit specific memory T cell responses against ebolavirus, according to new research presented at ECCMID.
A recently discovered species of the ebolavirus, the Bombali virus, has been identified in bats in Kenya, marking the first time any ebolavirus has been found in wildlife on the east coast of Africa.
Take a look at this month’s industry headlines including news on Sanofi’s Dengvaxia® vaccine from the USA and the Philippines, clinical trial results for RSV vaccines and HIV injectables and new acquisitions for Merck.
A new population-based survey has reported that low levels of public trust could have impacted the Ebola control efforts in the Democratic Republic of Congo, with a quarter of individuals not believing the virus was real and refusing vaccination.
A review of Venezuela’s current crisis has given cause for concern, highlighting the increased rate of re-emergence and spread of vector-borne diseases such as malaria, Chagas disease, dengue and Zika virus.
Researchers from the Wistar Institute have engineered a synthetic DNA vaccine able to provide potent immunity against the emerging Mayaro virus in mice models.
Take a look at this month’s industry headlines including an FDA approval for a vaccine protecting against six diseases, positive clinical trial results for bacteraemia and dengue vaccines and new funding for CRSIPR-based antimicrobials.
Madariaga virus has been identified as the cause of acute febrile illness in eight children in Haiti between 2015 and 2016 – the first time it has been discovered in the country.
An mRNA-based vaccine has been demonstrated to protect against Powassan virus in mice, in addition to also conferring protection against the more distantly related Langat virus.
Ebola case numbers reach 426 in the current outbreak in the Democratic Republic of Congo, making this the second largest ever seen for the virus.
